regn-20260730 0000872589 false 0000872589 2026-07-30 2026-07-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2026 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 777 Old Saw Mill River Road , Tarrytown , New York 10591-6707 (Address of Principal Executive Offices, including zip code) ( 914 ) 847-7000 Registrant's telephone number, including area code Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock - par value $.001 per share REGN NASDAQ Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition. On July 30, 2026, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended June 30, 2026. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release, dated July 30, 2026, Reporting Second Quarter 2026 Financial and Operating Results. 104   Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 30, 2026 REGENERON PHARMACEUTICALS, INC. By: /s/ Joseph J. LaRosa Name: Joseph J. LaRosa Title: Executive Vice President, General Counsel and Secretary

Regeneron Pharmaceuticals announced its second quarter 2026 financial results on July 30, 2026, providing investors with an overview of the company's operational performance and pipeline developments during the quarter ended June 30, 2026.

On July 30, 2026, Regeneron Pharmaceuticals, Inc. announced its financial and operating results for the quarter ended June 30, 2026. The results were detailed in a press release, which was also furnished as Exhibit 99.1 to the SEC. The financial highlights included key performance metrics for the quarter, reflecting the company's operational efficiency and market performance. This event occurred on the same day as the filing, establishing its recency and relevance for investors and stakeholders.

Regeneron Pharmaceuticals, Inc.

AI Executive Summary

Key Takeaways

Raw Filing Content

Filing Overview

What This Means